TRVI

Trevi Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine that acts on opioid receptors in the cough reflex arc to treat chronic cough. Its lead program targets chronic cough tied to idiopathic pulmonary fibrosis, with additional programs for other interstitial lung diseases and refractory chronic cough. The company has kept worldwide commercial rights to Haduvio.

CUSIP: 89532M101HealthcareUS1 holder

Ownership Activity Financials Filings

TRVI

TRVI

Results of Operations and Financial Condition

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition